How are comparability studies designed for manufacturing process changes?

Comparability demonstrates equivalent product quality after manufacturing changes: 1) Risk assessment - categorize change magnitude and potential quality impact; determine testing scope. ICH Q5E provides framework. 2) Analytical comparability - extensive physicochemical characterization (primary structure, higher-order structure, PTMs, purity profiles, potency); multiple batches before and after; statistical equivalence testing. 3) Functional assessment - mechanism-relevant bioassays; receptor binding; effector functions. 4) Stability - confirm comparable stability profiles; accelerated and real-time studies. 5) Non-clinical studies - PK, toxicity if significant change; often bridging studies sufficient. 6) Clinical bridging - may require PK study demonstrating comparable exposure; efficacy/safety studies rarely needed for well-characterized products. Regulatory strategy: prospective agency engagement for major changes; post-approval change protocols for anticipated changes. Comparability protocol in BLA/MAA allows pre-defined changes without prior approval. Documentation must clearly demonstrate no adverse impact on safety, identity, purity, or potency.